Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Managing Patients with Psoriasis and Comorbidities: Cases, Evidence and Action Plans

Live Webcast: Wednesday, January 10, 2018
12:00 PM - 1:00 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, January 10, 2019

Faculty


Joel M. Gelfand, MD, MSCEJoel M. Gelfand, MD, MSCE 
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director
Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Junko Takeshita, MD, PhD, MSCEJunko Takeshita, MD, PhD, MSCE 
Assistant Professor of Dermatology
Assistant Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Statement of Need

Psoriasis is a common chronic inflammatory skin condition that affects 3% to 4% of adults in the United States. Genetic susceptibility, immune dysregulation, and environmental factors are all thought to play a role in the development of the condition. Immunopathogenic studies have revealed that tumor necrosis factor alpha (TNF-α) and interleukins (IL-12, IL-17, IL-22, IL-23) are key cytokines involved in the pathogenesis of psoriasis. In recent years, there has been a focus on the development of treatment agents targeting these inflammatory cytokines. Despite the availability of effective treatments for psoriasis, physicians often fail to recognize psoriasis as a systemic inflammatory disease, resulting in significant undertreatment. Specifically, moderate and severe psoriasis are often treated with topical agents rather than more potent biologic and oral treatments, contributing to suboptimal outcomes and poor patient satisfaction.

In this CME Outfitters webinar, participants will be presented with a real-world case scenario intermixed with nationally-known, expert faculty discussing the latest clinical data, guidelines, and quality measures and how they apply to the case as we add layers of complexity to our patient scenario. Finally, faculty will discuss creating personalized clinical action plans for patients with psoriasis and take questions during dedicated time for Q & A.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathways.
  • Identify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selection.
  • Select appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatments.

The following learning objectives pertain only to those requesting CNE credit:

  • Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathways.
  • Identify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selection.
  • Describe appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatment.

Financial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Dermatologists, Physician Assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriasis

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.10 CEUs) Universal Activity Number:
Live: 0376-0000-18-002-L01-P
Enduring: 0376-0000-18-002-H01-P

Type: Knowledge-based

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST25317 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc. Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Coherus Biosciences; Dermira Inc.; Dr. Reddy?s Laboratories Ltd.; Janssen Biologics, Inc.; Menlo Therapeutics; Novartis Corporation; Pfizer Inc.; Sanofi; and Regeneron Pharmaceuticals, Inc. He receives other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.

Dr. Takeshita reports that she receives research grants from Pfizer Inc.

Daniela V. DiBiase, MS (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

WC-039-011018-45

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download